An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

Two previously conducted rivaroxaban studies showed that, separately, renal impairment (RI) and concomitant administration of erythromycin (P-glycoprotein and moderate cytochrome P450 3A4 [CYP3A4] inhibitor) can result in increases in rivaroxaban exposure. However, these studies did not assess the p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Pharmacol
Päätekijät: Moore, Kenneth T, Vaidyanathan, Seema, Natarajan, Jaya, Ariyawansa, Jay, Haskell, Lloyd, Turner, Kenneth C
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BlackWell Publishing Ltd 2014
Aiheet:
Drug-Drug Interactions
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4241044/
https://ncbi.nlm.nih.gov/pubmed/24964176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.352
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia